CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

(Curcumin + doxorubicin) by Immix BioPharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 24, 2023

Gamida Cell Ltd Patent: Method for Preparing Transplantable NK Cell Fraction

Share this article According to GlobalData’s company profile on Gamida Cell, T-cell culturing was a key innovation area identified from patents. Gamida Cell‘s grant share

March 29, 2024

Scale Biosciences announces ScalePlex technology to simplify single cell genomics studies of any scale

Novel multiplexing technology enables seamless sample pooling facilitating cost-efficient single cell experiments for compound screening and translational research.

June 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.